On December 11, 2025, WixBio successfully fulfilled a repeat order from an African customer, supplying coccidiosis tetravalent live vaccine in the 1,000-dose presentation. The product has gained broad acceptance across Africa and Southeast Asia due to its consistent immunogenicity and field efficacy, serving as an important tool for coccidiosis control in broiler and breeder operations.
Coccidiosis remains one of the most significant parasitic diseases affecting the global poultry industry, causing retarded growth, reduced feed conversion efficiency, and, in severe cases, elevated mortality. The WixBio tetravalent live vaccine incorporates four major pathogenic Eimeria species, inducing robust cross-protective immunity against locally prevalent field strains and substantially reducing the risk of clinical disease.
This repeat purchase reflects the customer’s confidence in the quality, immunogenic efficacy, and technical support provided by WixBio. To address varying regional disease patterns and regulatory requirements, WixBio maintains a customer-oriented approach by offering customized strain combinations, dosage forms, and packaging options while adhering strictly to international Good Manufacturing Practice (GMP) standards to ensure product safety and batch-to-batch consistency.
For logistics and delivery, WixBio employs specialized cold-chain transportation protocols tailored to the temperature- and time-sensitive nature of live vaccines, maintaining product viability throughout the supply chain from manufacturing facility to end user.
The head of WixBio’s International Business Division stated, “The continued strong demand for our tetravalent coccidiosis live vaccine in Africa and Southeast Asia reflects our commitment to localized service and precise response to regional needs. Moving forward, we will further expand our product portfolio and enhance technical support to deliver more effective and reliable parasitic disease control solutions to customers worldwide.”
